Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine - PubMed (original) (raw)
. 2001 Apr 6;292(5514):69-74.
doi: 10.1126/science.1058915.
F Villinger, J D Altman, S L Lydy, S P O'Neil, S I Staprans, D C Montefiori, Y Xu, J G Herndon, L S Wyatt, M A Candido, N L Kozyr, P L Earl, J M Smith, H L Ma, B D Grimm, M L Hulsey, J Miller, H M McClure, J M McNicholl, B Moss, H L Robinson
Affiliations
- PMID: 11393868
- DOI: 10.1126/science.1058915
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
R R Amara et al. Science. 2001.
Abstract
Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
Similar articles
- Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, Robinson HL. Amara RR, et al. Vaccine. 2002 May 6;20(15):1949-55. doi: 10.1016/s0264-410x(02)00076-2. Vaccine. 2002. PMID: 11983252 Review. - Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI. Horton H, et al. J Virol. 2002 Jul;76(14):7187-202. doi: 10.1128/jvi.76.14.7187-7202.2002. J Virol. 2002. PMID: 12072518 Free PMC article. Clinical Trial. - CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. Kwa S, et al. J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11. J Virol. 2014. PMID: 24920805 Free PMC article. - Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L, Mulvania T, Anderson D, Greenberg PD, Hu SL, Haigwood NL. Doria-Rose NA, et al. J Virol. 2003 Nov;77(21):11563-77. doi: 10.1128/jvi.77.21.11563-11577.2003. J Virol. 2003. PMID: 14557642 Free PMC article. - Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
Chea LS, Amara RR. Chea LS, et al. Expert Rev Vaccines. 2017 Oct;16(10):973-985. doi: 10.1080/14760584.2017.1371594. Epub 2017 Sep 4. Expert Rev Vaccines. 2017. PMID: 28838267 Free PMC article. Review.
Cited by
- Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing.
Bhattacharya S, Jenkins MC, Keshavarz-Joud P, Bourque AR, White K, Alvarez Barkane AM, Bryksin AV, Hernandez C, Kopylov M, Finn MG. Bhattacharya S, et al. ACS Nano. 2024 Jul 23;18(31):20083-100. doi: 10.1021/acsnano.4c00949. Online ahead of print. ACS Nano. 2024. PMID: 39041587 Free PMC article. - Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing.
Bhattacharya S, Jenkins MC, Keshavarz-Joud P, Bourque AR, White K, Alvarez Barkane AM, Bryksin AV, Hernandez C, Kopylov M, Finn MG. Bhattacharya S, et al. bioRxiv [Preprint]. 2024 Feb 26:2024.02.24.581861. doi: 10.1101/2024.02.24.581861. bioRxiv. 2024. PMID: 38464232 Free PMC article. Updated. Preprint. - High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope.
Mopuri R, Welbourn S, Charles T, Ralli-Jain P, Rosales D, Burton S, Aftab A, Karunakaran K, Pellegrini K, Kilembe W, Karita E, Gnanakaran S, Upadhyay AA, Bosinger SE, Derdeyn CA. Mopuri R, et al. PLoS Pathog. 2023 Oct 25;19(10):e1011717. doi: 10.1371/journal.ppat.1011717. eCollection 2023 Oct. PLoS Pathog. 2023. PMID: 37878666 Free PMC article. - Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.
Bollimpelli VS, Reddy PBJ, Gangadhara S, Charles TP, Burton SL, Tharp GK, Styles TM, Labranche CC, Smith JC, Upadhyay AA, Sahoo A, Legere T, Shiferaw A, Velu V, Yu T, Tomai M, Vasilakos J, Kasturi SP, Shaw GM, Montefiori D, Bosinger SE, Kozlowski PA, Pulendran B, Derdeyn CA, Hunter E, Amara RR. Bollimpelli VS, et al. Nat Commun. 2023 Aug 8;14(1):4789. doi: 10.1038/s41467-023-40430-7. Nat Commun. 2023. PMID: 37553348 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical